Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cetuximab/Bevacizumab Followed by FOLFOX+Bevacizumab With or Without Cetuximab in Advanced Colorectal Cancer
NCT00571740Phase 2Withdrawn
- Sponsor
- Cancer and Leukemia Group B
- Modality
- Monoclonal Antibodies
01
Overview
Phase 2, randomised, open-label trial of KL-140 in colorectal cancer (CRC) (2 arms), sponsored by Cancer and Leukemia Group B. Primary endpoint: Progression-free survival rate at 6 months. Status: withdrawn.
02
Drugs
KL-140
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT00571740.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00571740.